Skip to main content

Advertisement

Log in

A systematic medline analysis of therapeutic approaches in ankylosing spondylitis

  • Review
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

Ankylosing spondylitis (AS) is a chronic inflammatory disorder involving the sacroiliac joints (SIJs), spine and less frequently the peripheral joints. Traditionally, it is well recognised that AS is a challenging disease to manage due to the lack of effective therapeutic options. Current evidence would suggest this has changed and there are now a number of therapies available that provide persistent control of inflammatory symptoms with improvement in daily function. NSAIDs remain the first step in patient treatment. Sulphasalazine may be effective in peripheral arthritis and there are emerging data to support its use in early inflammatory back pain. Studies have shown that pamidronate and steroid injection into SIJ have a symptom-modifying effect in AS. Current data suggest that anti-TNF treatment promises early benefit which is likely to continue in the longer term. Treatment with biologics should be considered sooner rather than later in the management of AS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Feldtkeller E, Khan MA, van der Heijde D, van der Linden S, Braun J (2003) Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. Rheumatol Int 23(2):61–66

    PubMed  Google Scholar 

  2. Carette S, Graham D, Little H, Rubenstein J, Rosen P (1983) The natural disease course of ankylosing spondylitis. Arthritis Rheum 26(2):186–190. doi:10.1002/art.1780260210

    Article  PubMed  CAS  Google Scholar 

  3. Gran JT, Skomsvoll JF (1997) The outcome of ankylosing spondylitis; a study of 100 patients. Br J Rheumatol 36(7):766–771. doi:10.1093/rheumatology/36.7.766

    Article  PubMed  CAS  Google Scholar 

  4. Ward MM (1999) Health-related quality of life in ankylosing spondylitis: a survey of 175 patients. Arthritis Care Res 12(4):247–255. doi:10.1002/1529-0131(199908)12:4<247::AID-ART3>3.0.CO;2-H

    Article  PubMed  CAS  Google Scholar 

  5. Dagfinrud H, Vollestad NK, Loge JH, Kvien TK, Mengshoel AM (2005) Fatique in patients with ankylosing spondylitis: a comparison with the general population and associations with clinical and self-reported measures. Arthritis Rheum 53(1):5–11. doi:10.1002/art.20910

    Article  PubMed  Google Scholar 

  6. Ward MM (2002) Functional disability predicts total costs in patients with ankylosing spondylitis. Arthritis Rheum 46(1):223–231. doi:10.1002/1529-0131(200201)46:1<223::AID-ART498>3.0.CO;2-#

    Article  PubMed  Google Scholar 

  7. Kobelt G, Andlin-Sobocki P, Brophy S, Jonsson L, Calin A, Braun J (2004) The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (remicade). Rheumatology 43(9):1158–1166. doi:10.1093/rheumatology/keh271

    Article  PubMed  CAS  Google Scholar 

  8. Boonen A, van der Heijde D, Landewe R, Guillemin F, Rutten-van Molken M, Dougados M et al (2003) Direct costs of ankylosing spondylitis and its determinants: an analysis among three European countries. Ann Rheum Dis 62(8):732–740. doi:10.1136/ard.62.8.732

    Article  PubMed  CAS  Google Scholar 

  9. van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27(4):361–368. doi:10.1002/art.1780270401

    Article  PubMed  Google Scholar 

  10. Rudwaleit M, van der Heijde D, Khan MA, Braun J, Sieper J (2004) How to diagnose axial spondyloarthritis early. Ann Rheum Dis 63(5):535–543. doi:10.1136/ard.2003.011247

    Article  PubMed  CAS  Google Scholar 

  11. Rudwaleit M, Listing J, Brandt J, Braun J, Sieper J (2004) Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis 63(6):665–670. doi:10.1136/ard.2003.016386

    Article  PubMed  CAS  Google Scholar 

  12. Dougados M, Dijkmans B, Khan M, Maksymowych W, van der Linden S, Brandt J (2002) Conventional treatment for ankylosing spondylitis. Ann Rheum Dis 61(Suppl 3):40–50

    Google Scholar 

  13. Shekelle PG, Woolf SH, Eccles M, Grimshaw J (1999) Clinical guidelines: developing guidelines. BMJ 318(7183):593–596

    PubMed  CAS  Google Scholar 

  14. Brandt J, Haibel H, Cornely D et al (2000) Successful treatment of active ankylosing spondylitis with anti-tumour necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 43(6):1346–1352. doi:10.1002/1529-0131(200006)43:6<1346::AID-ANR18>3.0.CO;2-E

    Article  PubMed  CAS  Google Scholar 

  15. Van Den Bosch F, Kruithof E, Baeten D, De Keyser F, Mielants H, Veys EM (2000) Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis 59(6):428–433. doi:10.1136/ard.59.6.428

    Article  PubMed  Google Scholar 

  16. Kruithof E, Van den Bosch F, Baeten D et al (2002) Repeated infusions of infliximab, a chimeric anti-TNF alpha monoclonal antibody, in patients with active spondyloarthropathy: one year follow up. Ann Rheum Dis 61(3):207–212. doi:10.1136/ard.61.3.207

    Article  PubMed  CAS  Google Scholar 

  17. Stone M, Salonen D, Lax M, Payne U, Lapp V, Inman R (2001) Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis. J Rheumatol 28(7):1605–1614

    PubMed  CAS  Google Scholar 

  18. Maksymowych WP, Jhangri GS, Lambert RG et al (2002) Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety. J Rheumatol 29(5):959–965

    PubMed  CAS  Google Scholar 

  19. Braun J, Brandt J, Listing J et al (2002) Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 359(9313):1187–1193. doi:10.1016/S0140-6736(02)08215-6

    Article  PubMed  CAS  Google Scholar 

  20. Braun J, Brandt J, Listing J et al (2003) Long term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum 48(8):2224–2233. doi:10.1002/art.11104

    Article  PubMed  CAS  Google Scholar 

  21. Braun J, Brandt J, Listing J et al (2005) Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis 64(2):229–234. doi:10.1136/ard.2004.025130

    Article  PubMed  CAS  Google Scholar 

  22. Braun J, Baraliakos X, Brandt J et al (2005) Persistent clinical response to the anti TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years. Rheumatology 44(5):670–676. doi:10.1093/rheumatology/keh584

    Article  PubMed  CAS  Google Scholar 

  23. Braun J, Baraliakos X, Listing J et al (2008) Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. Ann Rheum Dis 67(3):340–345. doi:10.1136/ard.2007.075879

    Article  PubMed  CAS  Google Scholar 

  24. Sieper J, Baraliakos X, Listing J et al (2005) Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 years of treatment with the anti-tumour necrosis factor agent infliximab. Rheumatology 44(12):1525–1530. doi:10.1093/rheumatology/kei046

    Article  PubMed  CAS  Google Scholar 

  25. Braun J, Baraliakos X, Golder W et al (2003) Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum 48(4):1126–1136. doi:10.1002/art.10883

    Article  PubMed  CAS  Google Scholar 

  26. Marzo-Ortega H, McGonagle D, Jarrett S et al (2005) Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study. Ann Rheum Dis 64(11):1568–1575. doi:10.1136/ard.2004.022582

    Article  PubMed  CAS  Google Scholar 

  27. Perez-Guijo VC, Cravo AR, Castro Mdel C, Font P, Munoz-Gomariz E, Collantes-Estevez E (2007) Increased efficacy of infliximab associated with methotrexate in ankylosing spondylitis. Joint Bone Spine 74(3):254–258. doi:10.1016/j.jbspin.2006.08.005

    Article  PubMed  CAS  Google Scholar 

  28. Baraliakos X, Listing J, Rudwaleit M, Brandt J, Sieper J, Braun J (2005) Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab. Ann Rheum Dis 64(10):1462–1466. doi:10.1136/ard.2004.033472

    Article  PubMed  CAS  Google Scholar 

  29. Baraliakos X, Listing J, Brandt J et al (2007) Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-alpha antibody infliximab. Rheumatology 46(9):1450–1453. doi:10.1093/rheumatology/kem166

    Article  PubMed  CAS  Google Scholar 

  30. van der Heijde D, Dijkmans B, Geusens P et al (2005) Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomised, placebo-controlled trial (ASSERT). Arthritis Rheum 52(2):582–591. doi:10.1002/art.20852

    Article  PubMed  CAS  Google Scholar 

  31. Baraliakos X, Listing J, Brandt J et al (2005) Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther 7(3):439–444. doi:10.1186/ar1693

    Article  CAS  Google Scholar 

  32. Baraliakos X, Listing J, Rudwaleit M et al (2007) Safety and efficacy of readministration of infliximab after long term continuous therapy and withdrawal in patients with ankylosing spondylitis. J Rheumatol 34(3):510–515

    PubMed  CAS  Google Scholar 

  33. Gossec L, Le Henanff A, Breban M et al (2006) Continuation of treatment with infliximab in ankylosing spondylitis: 2-yr open follow up. Rheumatology 45(7):859–862. doi:10.1093/rheumatology/kel015

    Article  PubMed  CAS  Google Scholar 

  34. Keeling S, Oswald A, Russell AS, Maksymowych WP (2006) Prospective observational analysis of the efficacy and safety of low-dose (3 mg/kg) Infliximab in ankylosing spondylitis: 4-year follow up. J Rheumatol 33(3):558–561

    PubMed  CAS  Google Scholar 

  35. Cheung PP, Tymms KE, Wilson BJ et al (2008) Inflximab in severe active ankylosing spondylitis with spinal ankylosis. Intern Med J 38(6):396–401. doi:10.1111/j.1445-5994.2007.01599.x

    Article  PubMed  CAS  Google Scholar 

  36. Marzo-Ortega H, McGonagle D, O’Connor P, Emery P (2001) Efficacy of etanercept in the treatment of the entheseal pathology in resistant Spondylarthropathy: a clinical and magnetic resonance imaging study. Arthritis Rheum 44(9):2112–2117. doi:10.1002/1529-0131(200109)44:9<2112::AID-ART363>3.0.CO;2-H

    Article  PubMed  CAS  Google Scholar 

  37. Gorman JD, Sack KE, Davis JC (2002) Treatment of ankylosing spondylitis by inhibition of tumour necrosis factor alpha. N Engl J Med 346(18):1349–1356. doi:10.1056/NEJMoa012664

    Article  PubMed  CAS  Google Scholar 

  38. Davis JC, Van der Heijde D, Braun J et al (2003) Recombinant human tumour necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomised controlled trial. Arthritis Rheum 48(11):3230–3236. doi:10.1002/art.11325

    Article  PubMed  CAS  Google Scholar 

  39. Baraliakos X, Davis J, Tsuji W, Braun J (2005) Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept. Arthritis Rheum 52(4):1216–1223. doi:10.1002/art.20977

    Article  PubMed  CAS  Google Scholar 

  40. Davis JC, Van der Heijde DM, Braun J et al (2005) Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. Ann Rheum Dis 64(11):1557–1562. doi:10.1136/ard.2004.035105

    Article  PubMed  CAS  Google Scholar 

  41. Davis JC, Van der Heijde DM, Braun J et al (2007) Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis 67(3):346–352. doi:10.1136/ard.2007.078139

    Article  PubMed  CAS  Google Scholar 

  42. Brandt J, Khariouzov A, Listing J et al (2003) Six-month results of a double- blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 48(6):1667–1675. doi:10.1002/art.11017

    Article  PubMed  CAS  Google Scholar 

  43. Brandt J, Listing J, Haibel H et al (2005) Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis. Rheumatology 44(3):342–348. doi:10.1093/rheumatology/keh475

    Article  PubMed  CAS  Google Scholar 

  44. Baraliakos X, Brandt J, Listing J et al (2005) Outcome of patients with active ankylosing spondylitis after twor years of therapy with etanercept: clinical and magnetic esonance imaging Data. Arthritis Rheum 53(6):856–863. doi:10.1002/art.21588

    Article  PubMed  CAS  Google Scholar 

  45. Rudwaleit M, Baraliakos X, Listing J, Brandt J, Sieper J, Braun J (2005) Magnetic resonance imaging of the spine and the sacroiliac joint in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanercept. Ann Rheum Dis 64(9):1305–1310. doi:10.1136/ard.2004.032441

    Article  PubMed  CAS  Google Scholar 

  46. Calin A, Dijkmans BA, Emery P et al (2004) Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 63(12):1594–1600. doi:10.1136/ard.2004.020875

    Article  PubMed  CAS  Google Scholar 

  47. Braun J, McHugh N, Singh A, Wajdula JS, Sato R (2007) Improvement in patient- reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly. Rheumatology 46(6):999–1004. doi:10.1093/rheumatology/kem069

    Article  PubMed  CAS  Google Scholar 

  48. Haibel H, Rudwaleit M, Brandt HC et al (2006) Adalimumab reduces spinal symptoms in active ankylosing spondyltis: clinical and magnetic resonance imaging results of a fifty-two week open-label trial. Arthritis Rheum 54(2):678–681. doi:10.1002/art.21563

    Article  PubMed  CAS  Google Scholar 

  49. van der Heijde D, Kivitz A, Schiff MH et al (2006) Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 54(7):2136–2146. doi:10.1002/art.21913

    Article  PubMed  CAS  Google Scholar 

  50. van der Heijde D, Pangan AL, Schiff MH et al (2008) Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis. Ann Rheum Dis 67(9):1218–1221. doi:10.1136/ard.2007.082529

    Article  PubMed  CAS  Google Scholar 

  51. Tan AL, Marzo-Ortega H, O’ Connor P, Fraser A, Emery P, McGonagle D (2004) Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study. Ann Rheum Dis 63(9):1041–1045. doi:10.1136/ard.2004.020800

    Article  PubMed  CAS  Google Scholar 

  52. Haibel H, Rudwaleit M, Listing J, Sieper J (2005) Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. Ann Rheum Dis 64(2):296–298. doi:10.1136/ard.2004.023176

    Article  PubMed  CAS  Google Scholar 

  53. Blue Cross Blue Shield Association Technology Evaluation Centre (BCBS) (2003) Off label uses for tumor necrosis factor inhibitors in ankylosing spondylitis, ulcerative colitis, and psoriasis, Chicago, p 61

  54. Canadian Coordinating Office for Health Technology Assessment (CCOHTA) (2004) Infliximab (Remicade TM) for the treatment of ankylosing spondylitis, Ottawa, p 54

  55. Canadian Coordinating Office for Health Technology Assessment (CCOHTA) (2004) Etanercept for the treatment of ankylosing spondylitis, Ottawa, p 53

  56. BSR guidelines for prescribing TNF alpha blockers in adults with ankylosing spondylitis (2004) The British Society for Rheumatology. http://www.rheumatology.org.uk

  57. Barkham N, Kong KO, Tennant A et al (2005) The unmet need for anti-tumour necrosis factor (anti-TNF) therapy in ankylosing spondylitis. Rheumatology 44(10):1277–1281. doi:10.1093/rheumatology/keh713

    Article  PubMed  CAS  Google Scholar 

  58. Sampaio-Barros PD, Costallat LT, Bertolo MB, Neto JF, Samara AM (2000) Methotrexate in the treatment of ankylosing spondylitis. Scand J Rheumatol 29(3):1160–1162

    Google Scholar 

  59. Biasi D, Carletto A, Caramaschi P, Pacor ML, Maleknia T, Bambara LM (2000) Efficacy of methotrexate in the treatment of ankylosing spondylitis: a three year open study. Clin Rheumatol 19(2):114–117. doi:10.1007/s100670050027

    Article  PubMed  CAS  Google Scholar 

  60. Altan L, Bingol U, Karakoc Y, Aydiner S, Yurtkuran M (2001) Clinical investigation of methotrexate in the treatment of ankylosing spondylitis. Scand J Rheumatol 30(5):255–259. doi:10.1080/030097401753180318

    Article  PubMed  CAS  Google Scholar 

  61. Roychowdhury B, Bintley-Bagot S, Bulgen DY, Thompson RN, Tunn EJ, Moots RJ (2002) Is methotrexate effective in ankylosing spondylitis? Rheumatology 41(11):1330–1332. doi:10.1093/rheumatology/41.11.1330

    Article  PubMed  CAS  Google Scholar 

  62. Gonzalez-lopez L, Garcia-Gonzalez A, Vazquez-Del-Mercado M, Munoz-Valle JF, Gamez-Nava JI (2004) Efficacy of methotrexate in ankylosing spondylitis: a randomized, double blind, placebo controlled trial. J Rheumatol 31(8):1568–1574

    PubMed  CAS  Google Scholar 

  63. Haibel H, Brandt HC, Song IH et al (2007) No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial. Ann Rheum Dis 66(3):419–421. doi:10.1136/ard.2006.054098

    Article  PubMed  CAS  Google Scholar 

  64. Chen J, Liu C, Lin J (2006) Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev 4:CD004524 Review

    PubMed  Google Scholar 

  65. Feltelius N, Hallgren R (1986) Sulphasalazine in ankylosing spondylitis. Ann Rheum Dis 45(5):396–399. doi:10.1136/ard.45.5.396

    Article  PubMed  CAS  Google Scholar 

  66. Nissila M, Lehtinen K, Leirisalo-Repo M, Luukkainen R, Mutru O, Yli-kerttula U (1988) Sulphasalazine in the treatment of ankylosing spondylitis. A twenty-six week, placebo-controlled trial. Arthritis Rheum 31(9):1111–1116. doi:10.1002/art.1780310905

    Article  PubMed  CAS  Google Scholar 

  67. Davis MJ, Dawes PT, Beswick E, Lewin IV, Stanworth DR (1989) Sulphasalazine therapy in ankylosing spondylitis: its effect on disease activity, immunoglobulin A and the complex immunoglobulin A-alpha-1-antitrypsin. Br J Rheumatol 28(5):410–413. doi:10.1093/rheumatology/28.5.410

    Article  PubMed  CAS  Google Scholar 

  68. Taylor HG, Beswick EJ, Dawes PT (1991) Sulphasalazine in ankylosing spondylitis. A radiological, clinical and laboratory assessment. Clin Rheumatol 10(1):43–48. doi:10.1007/BF02208032

    Article  PubMed  CAS  Google Scholar 

  69. Kirwan J, Edwards A, Huitfeldt B, Thompson P, Currey H (1993) The course of established ankylosing spondylitis and the effects of sulphasalazine over 3 years. Br J Rheumatol 32(8):729–733. doi:10.1093/rheumatology/32.8.729

    Article  PubMed  CAS  Google Scholar 

  70. Dougados M, vam der Linden S, Leirisalo-Repo M et al (1995) Sulfasalazine in the treatment of spondyloarthropathy. A randomized, multi center, double-blind, placebo-controlled study. Arthritis Rheum 38(5):618–627. doi:10.1002/art.1780380507

    Article  PubMed  CAS  Google Scholar 

  71. Clegg DO, Reda DJ, Weisman MH et al (1996) Comparison of sulphasalazine and placebo in the treatment of ankylosing spondylitis. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 39(12):2004–2012. doi:10.1002/art.1780391209

    Article  PubMed  CAS  Google Scholar 

  72. Clegg DO, Reda DJ, Abdellatif M (1999) Comparison of sulfazalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondyloarthropathies. A Department of Veterans Affairs Cooperative Study. Arthritis Rheum 42(11):2325–2329. doi:10.1002/1529-0131(199911)42:11<2325::AID-ANR10>3.0.CO;2-C

    Article  PubMed  CAS  Google Scholar 

  73. Braun J, Zochling J, Baraliakos X et al (2006) Efficacy of sulphasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis- a multicentre randomised controlled trial. Ann Rheum Dis 65(9):1147–1153. doi:10.1136/ard.2006.052878

    Article  PubMed  CAS  Google Scholar 

  74. Ferraz MB, Tugwell P, Goldsmith CH, Atra E (1990) Meta analysis of sulfasalazine in ankylosing spondylitis. J Rheumatol 17(11):1482–1486

    PubMed  CAS  Google Scholar 

  75. Chen J, Liu C (2006) Is sulfazalazine effective in ankylosing spondylitis? A systematic review of randomized controlled trials. J Rheumatol 33(4):722–731

    PubMed  CAS  Google Scholar 

  76. Haibel H, Rudwaleit M, Braun J, Sieper J (2005) Six months open label trial of leflunamide in active ankylosing spondylitis. Ann Rheum Dis 64(1):124–126. doi:10.1136/ard.2003.019174

    Article  PubMed  CAS  Google Scholar 

  77. van Denderen JC, van der Paardt M, Nurmohamed MT, de Ryck YM, Dijkmans BA, van der Horst-Bruinsma IE et al (2005) Double blind, randomised, placebo controlled study of leflunomide in the treatment of active ankylosing spondylitis. Ann Rheum Dis 64(12):1761–1764. doi:10.1136/ard.2005.036491

    Article  PubMed  CAS  Google Scholar 

  78. Dougados M, Gueguen A, Nakache JP et al (1999) Ankylosing spondylitis: what is the optimum duration of a clinical study? A one year versus a 6 weeks non-steroidal anti-inflammatory drug trial. Rheumatology 38(3):235–244. doi:10.1093/rheumatology/38.3.235

    Article  PubMed  CAS  Google Scholar 

  79. Dougados M, Behier JM, Jolchine I et al (2001) Efficacy of celebrex, a cyclooxygenase 2- specific inhibitor, in the treatment of ankylosing spondylitis: a six-week controlled study with comparison against placebo and against a conventional non steroidal anti inflammatory drug. Arthritis Rheum 44(1):180–185. doi:10.1002/1529-0131(200101)44:1<180::AID-ANR24>3.0.CO;2-K

    Article  PubMed  CAS  Google Scholar 

  80. Wanders A, Heijde D, Landewe R et al (2005) Nonsteroidal anti-inflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomised controlled trial. Arthritis Rheum 52(6):1756–1765. doi:10.1002/art.21054

    Article  PubMed  CAS  Google Scholar 

  81. van der Heijde D, Baraf HS, Ramos-Remus C et al (2005) Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: result of a fifty-two week, randomized, controlled study. Arthritis Rheum 52(4):1205–1215. doi:10.1002/art.20985

    Article  PubMed  CAS  Google Scholar 

  82. Gossec L, van der Heijde D, Melian A et al (2005) Efficacy of cyclo-oxygenase-2 inhibition by etoricoxib and naproxen on the axial manifestations of ankylosing spondylitis in the presence of peripheral arthritis. Ann Rheum Dis 64(11):1563–1567. doi:10.1136/ard.2004.029611

    Article  PubMed  CAS  Google Scholar 

  83. Sieper J, Klopsch T, Richter M et al (2008) Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study. Ann Rheum Dis 67(3):323–329. doi:10.1136/ard.2007.075309

    Article  PubMed  CAS  Google Scholar 

  84. Maksymowych WP, Jhangri GS, Leclercq S, Skeith K, Yan A, Russell AS (1998) An open study of pamidronate in the treatment of refractory ankylosing spondylitis. J Rheumatol 25(4):714–717

    PubMed  CAS  Google Scholar 

  85. Maksymowych WP, Lambert R, Jhangri GS et al (2001) Clinical and radiological amelioration of refractory peripheral spondyloarthritis by pulse intravenous pamidronate therapy. J Rheumatol 28(1):144–155

    PubMed  CAS  Google Scholar 

  86. Maksymowych WP, Jhangri GS, Fitzgerald AA et al (2002) A six month randomised, controlled, double- blind, dose-response comparison of Intravenous pamidronate (60 mg vs 10 mg) in the treatment of non steroidal anti-inflammatory drug refractory ankylosing spondylitis. Arthritis Rheum 46(3):766–773. doi:10.1002/art.10139

    Article  PubMed  CAS  Google Scholar 

  87. Haibel H, Brandt J, Rudwaleit M, Soerensen H, Sieper J, Braun J (2003) Treatment of active ankylosing spondylitis with pamidronate. Rheumatology 42(8):1018–1020. doi:10.1093/rheumatology/keg256

    Article  PubMed  CAS  Google Scholar 

  88. Grover R, Shankar S, Aneja R, Marwaha V, Gupta R, Kumar A (2006) Treatment of ankylosing spondylitis with pamidronate: an open label study. Ann Rheum Dis 65(5):688–689. doi:10.1136/ard.2005.041392

    Article  PubMed  CAS  Google Scholar 

  89. Maugars Y, Mathis C, Vilon P, Prost A (1992) Corticosteriod injection of the sacroiliac joint in patients with seronegative spondyloarthropathy. Arthritis Rheum 35(5):564–568. doi:10.1002/art.1780350512

    Article  PubMed  CAS  Google Scholar 

  90. Braun J, Bollow M, Seyrekbasan F et al (1996) Computed tomography guided corticosteriod injection of the sacroiliac joint in patients with spondylarthropathy with sacroilitis: clinical outcome and follow-up by dynamic magnetic resonance imaging. J Rheumatol 23(4):659–664

    PubMed  CAS  Google Scholar 

  91. Maugars Y, Mathis C, Berthelot JM, Charlier C, Prost A (1996) Assessment of the efficacy of sacroiliac corticosteriod injections in spondyloarthropathies: a double-blind study. Br J Rheumatol 35(8):767–770. doi:10.1093/rheumatology/35.8.767

    Article  PubMed  CAS  Google Scholar 

  92. Gunaydin I, Pereira PL, Daikeler T et al (2000) Magnetic resonance imaging guided corticosteriod injection of the sacroiliac joints in patients with therapy resistant spondyloarthropathy: a pilot study. J Rheumatol 27(2):424–428

    PubMed  CAS  Google Scholar 

  93. Hanly JG, Mitchell M, MacMillan L, Mosher D, Sutton E (2000) Efficacy of sacroiliac corticosteriod injections in patients with inflammatory spondyloartropathy: results of a 6 month controlled study. J Rheumatol 27(3):719–722

    PubMed  CAS  Google Scholar 

  94. Rudwaleit M, Khan MA, Sieper J (2005) The challenge of diagnosis and classification in early ankylosing spondylitis. Do we need new criteria? Arthritis Rheum 52(4):1000–1008. doi:10.1002/art.20990

    Article  PubMed  Google Scholar 

  95. Kenny JB, Hughes PL, Whitehouse GH (1990) Discovertebral destruction in ankylosing spondylitis: the role of computed tomography and magnetic resonance imaging. Br J Radiol 63(750):448–455

    Article  PubMed  CAS  Google Scholar 

  96. Jevtic V, Kos-Golja M, Rozman B, McCall I (2000) Marginal erosive discovertebral “Romanus” lesions in ankylosing spondylitis demonstrated by contrast enhanced Gd-DTPA magnetic resonance imaging. Skeletal Radiol 29(1):27–33. doi:10.1007/s002560050005

    Article  PubMed  CAS  Google Scholar 

  97. Goh L, Suresh P, Gafoor A, Hughes P, Hickling P (2008) Disease activity in longstanding ankylosing spondylitis: a correlation of clinical and magnetic resonance imaging findings. Clin Rheum 27(4):449–455. doi:10.1007/s10067-007-0726-7

    Article  CAS  Google Scholar 

  98. Muche B, Bollow M, Francois RJ, Sieper J, Hamm B, Braun J (2003) Anatomic structures involved in early and late-stage sacroilitis in spondyloarthritis: a detailed analysis by contrast-enhanced magnetic resonance imaging. Arthritis Rheum 48(5):1374–1384. doi:10.1002/art.10934

    Article  PubMed  CAS  Google Scholar 

  99. Bredella MA, Steinbach LS, Morgan S, Ward M, Davis JC (2006) MRI of the sacroiliac joint in patients with moderate to severe ankylosing spondylitis. AJR Am J Roentgenol 187(6):1420–1426. doi:10.2214/AJR.05.1423

    Article  PubMed  Google Scholar 

  100. Maksymowych WP, Landewe R (2006) Imaging in ankylosing spondylitis. Best Pract Res Clin Rheumatol 20(3):507–519. doi:10.1016/j.berh.2006.03.006

    Article  PubMed  Google Scholar 

  101. Rudwaleit M, Schwarzlose S, Hilgert ES, Listing J, Braun J, Sieper J (2008) MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis. Ann Rheum Dis 67(9):1276–1281. doi:10.1136/ard.2007.073098

    Article  PubMed  CAS  Google Scholar 

  102. van der Heijde D, Landewe R, Einstein S et al (2008) Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 58(5):1324–1331. doi:10.1002/art.23471

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

We are grateful to K.J. Goh for his considerable support during preparation of this manuscript. The authors have declared no conflicts of interest.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to L. Goh.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Goh, L., Samanta, A. A systematic medline analysis of therapeutic approaches in ankylosing spondylitis. Rheumatol Int 29, 1123–1135 (2009). https://doi.org/10.1007/s00296-009-0973-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-009-0973-9

Keywords

Navigation